Literature DB >> 10225457

Evidence of LMP1-TRAF3 interactions in glycosphingolipid-rich complexes of lymphoblastoid and nasopharyngeal carcinoma cells.

H Ardila-Osorio1, B Clausse, Z Mishal, J Wiels, T Tursz, P Busson.   

Abstract

Latent membrane protein 1 (LMP1) is an Epstein-Barr virus (EBV) protein expressed in EBV-transformed B lymphocytes and in approximately 50% of nasopharyngeal carcinomas (NPCs). LMP1 signaling involves several cellular signaling intermediates, especially TNF receptor-associated factors (TRAFs). We have shown previously that LMP1 is highly concentrated in a cell fraction called glycosphingolipid-rich membrane complexes (GSL complexes). We report here that parallel accumulation of LMP1 and TRAF3, but not TRAF1 or TRADD, was observed in GSL complexes from lymphoblastoid and LMP1-positive NPC cells. In contrast, TRAF3 was not concentrated in GSL complexes from LMP1-negative cells. Binding of LMP1 and TRAF3 in GSL complexes was demonstrated in lymphoblastoid and NPC cells, by co-immunoprecipitation with both anti-LMP1 and anti-TRAF3 antibodies.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10225457     DOI: 10.1002/(sici)1097-0215(19990517)81:4<645::aid-ijc22>3.0.co;2-0

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  15 in total

1.  Differential signaling and tumor necrosis factor receptor-associated factor (TRAF) degradation mediated by CD40 and the Epstein-Barr virus oncoprotein latent membrane protein 1 (LMP1).

Authors:  K D Brown; B S Hostager; G A Bishop
Journal:  J Exp Med       Date:  2001-04-16       Impact factor: 14.307

Review 2.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

3.  CD40 and LMP-1 both signal from lipid rafts but LMP-1 assembles a distinct, more efficient signaling complex.

Authors:  A Kaykas; K Worringer; B Sugden
Journal:  EMBO J       Date:  2001-06-01       Impact factor: 11.598

4.  PRA1 promotes the intracellular trafficking and NF-kappaB signaling of EBV latent membrane protein 1.

Authors:  Hao-Ping Liu; Chih-Ching Wu; Yu-Sun Chang
Journal:  EMBO J       Date:  2006-08-17       Impact factor: 11.598

5.  The Epstein-Barr virus latent membrane protein 1 putative Janus kinase 3 (JAK3) binding domain does not mediate JAK3 association or activation in B-lymphoma or lymphoblastoid cell lines.

Authors:  Masaya Higuchi; Elliott Kieff; Kenneth M Izumi
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Epstein-Barr virus latent-infection membrane proteins are palmitoylated and raft-associated: protein 1 binds to the cytoskeleton through TNF receptor cytoplasmic factors.

Authors:  M Higuchi; K M Izumi; E Kieff
Journal:  Proc Natl Acad Sci U S A       Date:  2001-04-10       Impact factor: 11.205

7.  High molecular weight complex analysis of Epstein-Barr virus Latent Membrane Protein 1 (LMP-1): structural insights into LMP-1's homo-oligomerization and lipid raft association.

Authors:  Christopher M Wrobel; Timothy R Geiger; Rebecca N Nix; Aaron M Robitaille; Sandra Weigand; Alfredo Cervantes; Miguel Gonzalez; Jennifer M Martin
Journal:  Virus Res       Date:  2013-09-25       Impact factor: 3.303

8.  LMP1 transmembrane domain 1 and 2 (TM1-2) FWLY mediates intermolecular interactions with TM3-6 to activate NF-kappaB.

Authors:  Vishal Soni; Teruhito Yasui; Ellen Cahir-McFarland; Elliott Kieff
Journal:  J Virol       Date:  2006-08-23       Impact factor: 5.103

Review 9.  Roles for TNF-receptor associated factor 3 (TRAF3) in lymphocyte functions.

Authors:  Zuoan Yi; Wai Wai Lin; Laura L Stunz; Gail A Bishop
Journal:  Cytokine Growth Factor Rev       Date:  2013-12-25       Impact factor: 7.638

10.  Transcription profiling of Epstein-Barr virus nuclear antigen (EBNA)-1 expressing cells suggests targeting of chromatin remodeling complexes.

Authors:  Ramakrishna Sompallae; Simone Callegari; Siamak Akbari Kamranvar; Maria G Masucci
Journal:  PLoS One       Date:  2010-08-10       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.